Many intercellular signals are synthesised as transmembrane precursors that are released 19 by proteolytic cleavage ('shedding') from the cell surface. ADAM17, a membrane-tethered 20 metalloprotease, is the primary shedding enzyme responsible for the release of the 21 inflammatory cytokine TNFα and several EGF receptor ligands. ADAM17 exists in complex 22 with the rhomboid-like iRhom proteins, which act as cofactors that regulate ADAM17 23 substrate shedding. Here we report that the poorly characterised FERM domain-containing 24 protein FRMD8 is a new component of iRhom2/ADAM17 sheddase complex. FRMD8 binds 25 to the cytoplasmic N-terminus of iRhoms, and is necessary to stabilise the iRhoms and 26 ADAM17 beyond the Golgi. In the absence of FRMD8, iRhom2 and ADAM17 are degraded 27 via the endolysosomal pathway, resulting in the reduction of ADAM17-mediated shedding. 28
Introduction 33
The cell surface protease ADAM17 (also called TACE) mediates the release of many involved in the inflammatory responses to infection and tissue damage (Kalliolias and 38 Ivashkiv, 2016) . In addition, ADAM17 is the principle sheddase of the epidermal growth 39 factor (EGF) receptor ligands amphiregulin (AREG), transforming growth factor alpha 40 (TGFα), heparin-binding EGF (HB-EGF), epigen, and epiregulin (Sahin et al., 2004, Sahin 41 and Blobel, 2007) . The control of ADAM17 activity has therefore been the focus of much 42 fundamental and pharmaceutical research (reviewed in (Rose-John, 2013, Zunke and Rose-43 John, 2017)). We and others have previously reported that the rhomboid-like iRhom proteins 44 have a specific and extensive regulatory relationship with ADAM17, to the extent that iRhoms 45 can effectively be considered as regulatory subunits of the protease. iRhoms are members of 46 a wider family of evolutionarily related multi-pass membrane proteins, called the rhomboid-47 4 into macrophages. Consistent with our biochemical data, these mutant macrophages were 88 defective in their ability to release TNFα in response to lipopolysaccharide (LPS) stimulation, 89 demonstrating the pathophysiological importance of FRMD8 in the normal inflammatory 90 response by human macrophages. The in vivo significance of FRMD8 in regulating the 91 stability of the iRhom/ADAM17 shedding complex was further reinforced by our observation 92 that mature ADAM17 and iRhom2 protein levels are strongly reduced in tissues of FRMD8-93 deficent mice. 94
95
Results 96
FRMD8 is a novel interaction partner of iRhom1 and iRhom2 97
To investigate the molecular mechanisms that underlie iRhom2 functions, we performed a 98 mass spectrometry-based screen to identify new proteins that interact with human iRhom2. 99 C-terminally tagged protein (iRhom2-3xHA) was stably expressed in human embryonic 100 kidney (HEK) 293T cells and immunoprecipitated. The bead eluates containing 101 immunoprecipitated iRhom2 and its interacting proteins were analysed by label-free mass 102 spectrometry. As a negative control, we did the same analysis in parallel with 3xHA-tagged 103 UNC93B1, an unrelated polytopic protein that, like iRhom2, is predominantly located in the 104 ER (Koehn et al., 2007) (Fig. S1A ). Quantitative protein abundance data from three biological 105 replicates of Rhom2 and UNC93B1 co-immunoprecipitations were statistically analysed 106 using the Perseus software platform (Tyanova et al., 2016) . Validating the overall approach, 107 we detected ADAM17, the known iRhom2 interacting protein (Adrain et al., 2012 , McIlwain et 108 al., 2012 , Christova et al., 2013 as a statistically significant hit ( Fig. 1A, S1B ). Among other 109 significant hits were several 14-3-3 proteins (eta, epsilon, gamma, sigma, theta, zeta/delta) 110 and MAPK1/3 ( Fig. S1B ), which we have previously reported to participate in the regulation 111 of inflammatory signalling by phosphorylation of iRhom2 (Grieve et al., 2017) . The top hit by 112 a long way, however, was FRMD8 ( Fig. 1A, S1B ), a poorly studied protein that has not 113 previously been implicated in iRhom function, ADAM17 regulation, or growth factor or 114 cytokine signalling. 115
We confirmed the interaction between iRhom2 and FRMD8 by immunoprecipitation. C-116 terminally V5 tagged FRMD8 co-immunoprecipitated with either iRhom1-3xHA or iRhom2-117 3xHA (Fig. 1B) . Conversely, we pulled down both iRhom1-3xHA and iRhom2-3xHA with an 118 antibody against the V5 tag. Finally, we were also able to co-immunoprecipitate endogenous 119 FRMD8 with iRhom2-3xHA ( Fig. S1C ). Together these results identify FRMD8 as a bona fide 120 binding partner of iRhom1 and iRhom2 in human cells. 121 5 FRMD8 is required for iRhom function 122
As its name indicates, FRMD8 is a FERM (4.1/ezrin/radixin/moesin) domain-123 containing protein. It is predicted to be a soluble cytoplasmic protein, and the only report 124 about its function describes it as binding to the Wnt accessory receptor low-density 125 lipoprotein receptor-related protein 6 (LRP6), and negatively regulating Wnt signalling 126 (Kategaya et al., 2009 ). To investigate the functional significance of FRMD8 binding to 127 iRhoms, we examined the effects of loss of FRMD8 on iRhom function in HEK293T cells, 128 using both siRNA and CRISPR/Cas9-mediated gene deletion ( Fig. 2A, B ). In both cases, 129 loss of FRMD8 drastically reduced the protein levels of mature ADAM17 ( Fig. 2A, B ). This 130 effect was specific to ADAM17, as the maturation of its closest homologue, ADAM10, was 131 unaffected by loss of FRMD8 ( Fig. 2B ). Moreover, mature ADAM17 levels were rescued by 132 expression of FRMD8-V5 in FRMD8 knockout HEK293T cells ( Fig. 2C) , confirming that the 133 phenotype was caused by FRMD8 loss. Finally, in addition to this reduction of mature 134 ADAM17 caused by FRMD8 loss, we found a striking loss of ADAM17, but not ADAM10, on 135 the cell surface ( Fig. 2D ). These phenotypes partially phenocopy the loss of iRhoms 136 (Christova et al., 2013 , Grieve et al., 2017 , consistent with FRMD8 being needed for iRhoms 137 to act as positive regulators of ADAM17. 138
We also examined the consequences of loss of FRMD8 on ADAM17-dependent 139 signalling. The shedding of alkaline phosphatase (AP)-tagged EGF receptor ligands AREG 140 and HB-EGF, after stimulation with phorbol 12-myristate 13-acetate (PMA), were both 141 substantially reduced in FRMD8 knockout cells ( Fig. 2E ). To exclude the possibility that the 142 defect in FRMD8 knockout cells is an inability to respond to PMA, we measured both PMA-143 stimulated and unstimulated, constitutive shedding of AP-tagged TGFα, another major EGFR 144 ligand. Again, FRMD8 knockout cells released significantly less AP-TGFα compared to wild-145 type cells, both after stimulation but also after 20 h of constitutive shedding ( Fig. 2F ), 146 implying that mutant cells had fundamental defects in their ability to shed ADAM17 ligands, 147 regardless of PMA stimulation. To demonstrate that the release of ligands was indeed 148 caused by metalloprotease shedding and not simply an indication of leakage caused by cell 149 death, we showed that it was sensitive to the ADAM10/17 inhibitor GW280264X (GW) 150 ( Fig.2E, F) . Overall, as with ADAM17 maturation and localisation, the shedding defects in 151 FRMD8-deficient cells resemble those caused by the loss of iRhoms. 152 FRMD8 binds to the iRhom2 cytoplasmic N-terminus throughout the entire secretory 153 pathway 154
As described above, iRhoms regulate ADAM17 function at multiple stages: from ER-to-155
Golgi trafficking, to the activation of the sheddase at the cell surface. To address where 156 6 FRMD8 fits in this long-term relationship between iRhoms and ADAM17, we started by 157 analysing where in the secretory pathway FRMD8 binds to iRhom2. Immunofluorescent 158 staining of FRMD8-V5 with anti-V5 antibody confirmed what had been reported by Kategaya 159 et al.(2009) : the protein is detected in the cytoplasm and associated with the plasma 160 membrane (Fig. 3A) . When co-expressed with iRhom2-3xHA, we detected significant co-161 localisation between the proteins (Fig. 3A ) further confirming the interaction of FRMD8 and 162 iRhom2. Taking a more biochemical approach, immunoprecipitation of FRMD8 pulled down 163 both immature and mature ADAM17 (Fig. 2B ), indicating that there is a sufficiently stable 164 tripartite complex between FRMD8, iRhom2 and ADAM17 to allow FRMD8 to co-165 immunoprecipitate ADAM17. Note that FRMD8 did not pull down ADAM17 in cells mutant for 166 both iRhoms ( Fig. S2A ), implying that there is no direct link between them; instead both can 167 bind simultaneously to iRhom2. Significantly, FRMD8 binds iRhom2 when in complex with 168 immature ADAM17, which only exists in the ER and early Golgi apparatus, and also iRhom2 169 in complex with mature ADAM17, which exists in the trans-Golgi network and beyond; 170 together these data imply that FRMD8 binds to iRhom2 throughout the secretory pathway. 171
As a cytoplasmic protein, FRMD8 was likely to bind to the only substantial cytoplasmic 172 region of iRhom2, its N-terminus. We therefore made a set of iRhom2-3xHA N-terminal 173 deletion constructs ( Fig. 2C ) to locate the binding site. Deletion of the first 200 amino acids in 174 the N-terminus of iRhom2 did not disrupt FRMD8 binding, but no interaction was detected in 175 mutants greater than ∆300 ( Fig. 2D) , implying that the region between 200 and 300 amino 176 acids was necessary for FRMD8 binding. Although the N-terminal cytoplasmic tail of iRhom2 177 contains multiple regulatory phosphorylation sites ( Fig. S2B ), the FRMD8 binding region 178 does not overlap with the sites required for phosphorylation-dependent 14-3-3 binding 179 (Grieve et al., 2017 , Cavadas et al., 2017 . Consistent with this, the interaction of FRMD8 180 with iRhom2 was not changed upon PMA stimulation ( Fig. 2E ). Moreover, an iRhom2 181 mutant, in which 15 conserved phosphorylation sites have been mutated to alanine 182 (iRhom2 pDEAD , Fig. S2C ) (Grieve et al., 2017) , did not abolish the interaction to FRMD8 ( Fig.  183 2E), further demonstrating that the binding of FRMD8 to iRhom2 is independent of the 184 phosphorylation state of iRhom2. 185 Interestingly, the FRMD8 binding site is absent in a mouse iRhom2 mutant called curly-186 bare (cub), which lacks residues 1-268 (Hosur et al., 2014 , Siggs et al., 2014 . Sequence 187 alignment shows that the deletion of 268 amino acids in mouse iRhom2 corresponds to the 188 loss of residues 1-298 in the human protein ( Fig. 2C, S2B ). Consistent with this mapping 189 data, we found that whereas full-length mouse iRhom2 bound human FRMD8, the cub 190 mutant form cannot ( Fig. 3E ). This failure of FRMD8 binding presumably contributes to the 7 complex defects that underlie the cub phenotype (Johnson et al., 2003 , Hosur et al., 2014 , 192 Siggs et al., 2014 . 193
FRMD8 protects iRhom2 and ADAM17 from lysosomal degradation 194
These experiments demonstrate that FRMD8 binds to the cytoplasmic N-terminal 195 region of iRhom2, which has previously been shown to be required to stabilise ADAM17 at 196 the cell surface (Grieve et al., 2017) . We therefore tested whether FRMD8 is necessary for 197 iRhom2 to stabilise ADAM17. Treatment of HEK293T wild-type and FRMD8 knockout cells 198 with the lysosomal degradation inhibitors bafilomycin and ammonium chloride restored the 199 mature form of ADAM17 ( Fig. 4A; S3A ). This result explains the reduced level of mature 200 ADAM17 in FRMD8 knockout cells: it implies that the defect caused by loss of FRMD8 is not 201 a failure of ADAM17 maturation, but instead a failure to stabilise the mature form. In line with 202 this interpretation, the proteasomal inhibitor MG132 had no effect on the stability of mature 203 ADAM17 ( Fig. 4A ). We conclude that FRMD8 binding to iRhom2 acts to promote ADAM17 204 function by ensuring its stability after its maturation in the trans-Golgi network. 205
These data led us to test the hypothesis that FRMD8 might act as a stabilising factor 206 for the plasma membrane-localised iRhom/ADAM17 sheddase complex that controls the 207 release of growth factors and cytokines. When assaying total levels of exogenously 208 expressed iRhom2, we did not detect any difference between wild-type and FRMD8-deficient 209 cells ( Fig. S1C ). However, consistent with previous reports (Maney et al., 2015 , Grieve et al., 210 2017 , under these experimental conditions most iRhom2 is ER-localised ( Fig. S1A ) and the 211 cell surface fraction is relatively small. We therefore used cell surface immunostaining of 212 iRhom2 followed by flow cytometry to measure specifically the pool of iRhom2 at the cell 213 surface. In this case the result was clear: in the absence of FRMD8 there was a significant 214 loss of cell surface iRhom2 ( Fig. 4B ), although the reduction of total iRhom2 levels was not 215 detectable ( Fig. 4C ). Consistent with our conclusion that although FRMD8 binds continuously 216 to iRhom2, but primarily functions late in the iRhom2/ADAM17 relationship, we detected no 217 defects in the ER iRhom2/immature ADAM17 interaction in FRMD8 knockout cells ( Fig.  218 S3B), nor in the trafficking of iRhom2 from the ER to the Golgi (Fig. S3C ). 219
These results show that by binding to iRhom2, FRMD8 stabilises both iRhom2 and 220 mature ADAM17, protecting them from degradation. A more direct demonstration of this 221 stabilising function is provided by overexpressing FRMD8, which leads to increased levels of 222 exogenously expressed iRhom2 ( Fig. 4D ), as well as iRhom1 ( Fig. S3D ). Note that the 50 kD 223 N-terminally truncated fragment of iRhoms detected in western blots (Nakagawa et al., 2005, 224 Adrain et al., 2012, Maney et al., 2015) is not stabilised by FRMD8 expression ( Fig. 4D , 225 S3D). This iRhom fragment lacks the cytoplasmic tail, and therefore the binding site for 226 8 FRMD8, so its insensitivity to FRMD8 is consistent with our model. Intriguingly, the 227 stabilisation of iRhom2 and FRMD8 is mutual: overexpression of iRhom2 consistently led to 228 the stabilisation of endogenous FRMD8 protein ( Fig. 4E ), without affecting FRMD8 mRNA 229 levels ( Fig. 4F ). This indicates that the iRhom2-FRMD8 interaction leads to mutual 230 stabilisation of both proteins. 231
To ensure that our conclusion that FRMD8 stabilises iRhoms was not distorted by our 232 use of overexpressed proteins, and in the absence of a usable antibody against human 233 iRhom2, we used CRISPR/Cas9 to insert a triple HA tag into the RHBDF2 locus to express 234 endogenously C-terminally tagged iRhom2. siRNA-mediated knockdown of iRhom2 235 confirmed that this editing was successful (Fig. 5A ). The cells showed no defect in ADAM17 236 maturation ( Fig. 5A, S3E ), indicating that the tagged protein was functional. In these cells 237 FRMD8 overexpression led to an increase in endogenous iRhom2 levels ( Fig. 5A) ; 238 conversely, siRNA knockdown of FRMD8 caused a reduction of iRhom2 protein ( Fig. 5B ), 239 but no change of iRhom2 mRNA levels ( Fig. 5C ). Again, the 50 kDa iRhom2 fragment was 240 not affected by FRMD8 levels (Fig. 5A, B ). Parenthetically, this is the first reported evidence 241 for the existence of this iRhom fragment endogenously, although its functional significance 242 remains unclear. 243
To summarise our results to this point, we have discovered that by binding to the 244 iRhom2 cytoplasmic N-terminus, FRMD8 is necessary to stabilise the cell surface 245 iRhom2/ADAM17 shedding complex. In the absence of FRMD8, this enzyme complex is 246 degraded by the lysosome. FRMD8 is therefore an essential component of the sheddase 247 complex that releases ADAM17 substrates including cytokines and growth factors. 248 FRMD8 binding to iRhom2 is essential for inflammatory signalling in human 249 macrophages 250
We tested the pathophysiological significance of our conclusions by analysing the 251 consequence of loss of FRMD8 in human macrophages, which release TNFα in response to 252 tissue damage and inflammatory stimuli. To generate mutant human macrophages, we used 253 CRISPR/Cas9 to knock out FRMD8 in an iPSC line that had previously been generated from 254 dermal fibroblasts of a healthy female donor (Fernandes et al., 2016) . The FRMD8 knockout 255 and control iPSCs were analysed for deletions in the FRMD8 gene by PCR (Fig. S4A) , and a 256 normal karyotype was confirmed by single nucleotide polymorphism (SNP) analysis ( Fig.  257 S4B) before their differentiation into macrophages (Fig. 6A ). These mutant macrophages 258 expressed no detectable FRMD8 and, as in the HEK293T cells, showed severely reduced 259 levels of mature ADAM17 (Fig. 6B ). When challenged with the inflammatory trigger LPS, 260
TNFα shedding from the cells, as measured by ELISA, was reduced ( Fig. 6C ). Confirming 261 9 the expected specificity, the ADAM10 inhibitor GI254023X (GI) had no effect on TNFα 262 release from these cells, whereas GW, an inhibitor of both ADAM10 and ADAM17, further 263 reduced TNFα release ( Fig. 6C ). Although shedding was inhibited, induction of TNFα 264 expression by LPS was normal in these cells (Fig. S4C ). These results demonstrate that our 265 conclusions about the requirement for FRMD8 in ADAM17 function in cell culture models 266 does indeed apply to human macrophages. 267 Frmd8 -/mice showed that mature ADAM17 levels were reduced in all tissues examined 276 compared to tissues from a wild-type littermates (Fig. 6D ). This confirms that FRMD8 277 controls the level of mature ADAM17 in vivo. Of note, there was a major reduction of mature 278 ADAM17 levels in the brain, a tissue in which iRhom2 in almost completely absent but 279 iRhom1 levels are high (Christova et al., 2013 , Li et al., 2015 . This supports our hypothesis 280 that FRMD8 regulates mature ADAM17 levels through iRhom1 as well as iRhom2. We also 281 tested in vivo our conclusion that FRMD8 loss destabilises endogenous iRhoms ( Fig. 5B ). 282
Loss of FRMD8 in mice highlights its physiological role in stabilising the
Using an antibody that we had previously generated against mouse iRhom2 (Adrain et al., 283 2012), we analysed iRhom2 levels in Frmd8 +/+ and Frmd8 -/mouse tissues. In lung and skin, 284 both tissues with high iRhom2 expression (Christova et al., 2013), we detected a strong 285 decrease of iRhom2 protein levels in Frmd8 -/compared to wild-type ( Fig. 6E ). Tissue from 286
Rhbdf2 -/mice served as a control for the iRhom2 antibody specificity (Fig. 6E ). In summary, 287 our experiments in mice confirm the physiological importance of our prior conclusions: 288 FRMD8 is required in vivo to regulate the stability of the iRhom/ADAM17 shedding complex, 289 and is therefore a previously unrecognised essential component in regulating cytokine and 290 growth factor signalling. 291 292 Discussion 293 ADAM17 is the shedding enzyme that is responsible for not only the activation of 294 inflammatory TNFα signalling, but also the release from the cell surface of multiple EGF 295 10 family growth factors, and other proteins. Its regulation has therefore received much 296 attention, both from the perspective of fundamental cell biology and because of the proven 297 therapeutic significance of blocking TNFα (Monaco et al., 2015) . Here we report that FRMD8 298 is a new component of the regulatory machinery that controls the release of ADAM17 299 substrates, including TNFα. We identified FRMD8 as a prominent binding partner of iRhoms, 300 which are rhomboid-like proteins that act as regulatory cofactors of ADAM17. Our 301 subsequent experiments demonstrate that although FRMD8 binds to iRhoms throughout 302 their life cycle, its function appears to be confined to the later stages of their role in regulating 303 ADAM17. FRMD8 stabilises the iRhom2/ADAM17 complex at the cell surface, ensuring it is 304 available to shed TNFα and growth factors. We took advantage of iPSC technology to 305 generate human FRMD8 knockout macrophages, allowing us to confirm that the mechanistic 306 conclusions derived mostly from HEK293T cell models were indeed relevant to the human 307 cells that provide the primary inflammatory response. Finally, tissues from FRMD8 knockout 308 mice demonstrate the physiological importance of FRMD8 in a whole organism, and confirm 309 that it stabilises the iRhom/mature ADAM17 complex in vivo. 310
Bringing together all our results, we propose the following model of FRMD8 function in 311 ADAM17-dependent signalling: FRMD8 binds to the cytoplasmic domain of iRhoms 312 throughout the secretory pathway, forming a tripartite complex when iRhoms are also bound 313 to ADAM17. Despite this long-term relationship, we have found no evidence for a functional 314 role for FRMD8 in ER-to-Golgi trafficking or ADAM17 maturation. Instead, FRMD8 acts later, 315 to prevent the endolysosomal degradation of the iRhom/ADAM17 complex ( Fig. 7) . As we 316 have previously reported, it is this complex that is responsible for shedding ADAM17 317 substrates including, notably, TNFα. Without FRMD8, iRhoms and mature ADAM17 are 318 destabilised and the cell cannot shed TNFα in response to an inflammatory challenge. 319
Combined with our previous studies (Grieve et al. 2017) , this work has changed our 320 perspective on ADAM17, the central enzyme in cytokine and growth factor shedding. Our 321 evidence implies that it would be more appropriate to consider it as the active subunit of a 322 regulatory complex at the cell surface, where iRhoms provide regulatory functions ( In the only other paper about FRMD8 function, it was reported that FRMD8 (named 328 Bili, after the Drosophila mutation) negatively regulates Wnt signalling by binding to the LRP6 329 co-receptor, thereby preventing the recruitment of the signal transduction protein axin 330 (Kategaya et al., 2009 ). Although the signalling event being regulated is different, there is the 331 11 obvious parallel that in both cases FRMD8 binds to the cytoplasmic tail of a transmembrane 332 protein. In the case of Wnt signalling, this prevents the recruitment of axin; in the case of 333 iRhom function, we do not yet know what the next step in the molecular chain of events is, 334 but the cellular consequence is to prevent recruitment of iRhoms into the endolysosomal 335 degradation system. 336
Our results extend an important theme to emerge from a number of studies, namely 337 the significance of the cytoplasmic N-terminal region in regulating iRhom function. Several 338 reports indicate that N-terminal mutations cause complex phenotypes that combine aspects 339 of gain and loss of iRhom function, which is consistent with a regulatory function for this 340 region. First, the cub mutation, an N-terminal deletion in mouse iRhom2, does not abolish 341 protein function but instead modulates it in complex ways that are still poorly understood. cub 342 was described as a gain-of-function mutation that leads to constitutively elevated release of 343 amphiregulin, but is also reported to be defective in releasing TNFα (Hosur et al., 2014) . Our work now implies that the interface between FRMD8 and iRhoms might be a 368 useful target. This is supported, at least in principle, by our observation that even in cells with 369 complete loss of FRMD8, there is still a low level of mature ADAM17 at the cell surface, and 370 consequently residual TNFα shedding. Even very efficient pharmacological blocking of the 371 FRMD8/iRhom interaction would not, therefore, fully abolish inflammatory responses, 372 potentially reducing side effects. Consistent with this idea, mice with a hypomorphic mutation 373 in ADAM17 show that even only 5% of normal ADAM17 expression is sufficient to rescue 374 many aspects of the loss of function phenotype (Chalaris et al., 2010) . 375
In conclusion, our work demonstrates the cellular and physiological significance of 376 FRMD8 binding to iRhoms, and how this stabilises the iRhom/ADAM17 sheddase complex at 377 the cell surface. It also reinforces the picture that has begun to emerge of ADAM17 not 378 acting alone but instead being supported by at least two other regulatory proteins that act as 379 subunits of what is effectively an enzyme complex. This concept would help to explain how 380 the activity of such a powerful and versatile -and therefore potentially dangerous -shedding 381 enzyme is controlled with necessary precision. The next steps in fully revealing the role of 382 FRMD8 will be to analyse the phenotypic consequences of its loss in mice, which should 383 allow us to understand how the roles of FRMD8 roles in ADAM17 activation, Wnt signalling, 384 and any other potential functions, are integrated. Notwithstanding these physiological 385 questions, the work described here already provides a basis for beginning to investigate the 386 potential of targeting the FRMD8/iRhom interface for modulating the release of ADAM17 387 substrates. 388 389
Materials and methods 390

Molecular cloning 391
Human UNC93B1, human iRhom2 WT , iRhom2 Δ100 , iRhom2 Δ200 , iRhom2 Δ300 , iRhom2 Δ382 392 were amplified from human UNC93B1 (BC025669.1) and iRhom2 cDNA (NM_024599. and 10 ng/mL basic fibroblastic growth factor (bFGF, R&D)). Colonies were manually 548 selected and grown on geltrex in mTeSR1. Clones were analysed by western blot using the 549 anti-FRMD8 antibody, and PCR followed by Sanger sequencing. For PCR DNA was isolated 550 from iPSCs by incubation in DNA isolation buffer (10 mM Tris-HCl (pH 8), 1 mM EDTA, 25 551 mM NaCl, 200 ug/ml proteinase K added freshly) at 65°C for 30 min. Proteinase K was 552 inactivated at 95°C for 2 min. PCR using Q5 polymerase was performed according to the 553 manufacturer's instructions (New England Biolabs) using primers FRMD8_fw 554 (TGCAGATCCATGACGAGGA) and FRMD8_rev (GTGCTCGTGACAAGACAC). The PCR 555 product was purified and sequenced using the primer FRMD8_exon7_fw 556 (GCCAGAGTCTCTTTGCTG) for Sanger sequencing (Source Bioscience, Oxford). 557 558 Differentiation of iPSCs into macrophages 559 AH017-13 wild-type and FRMD8 knockout clones were analysed by Illumina 560
HumanOmniExpress24 single nucleotide polymorphism (SNP) array at the Wellcome Trust 561
Centre for Human Genetics at the University of Oxford and assessed using KaryoStudio 562 software to confirm normal karyotypes before differentiation into macrophages. For this study 563 iPSCs were differentiated into embryoid bodies (EBs) by mechanical lifting of iPSC colonies 564 and differentiated into macrophages as described in (van Wilgenburg et al., 2013) . Briefly, 565 iPSCs were grown on a feeder layer of MEFs in hES medium. A dense 10 cm 2 well of iPSCs 566 was scored into 10x 10 sections using a plastic pipette tip. The resulting 100 patches were 567 lifted with a cell scraper and cell clumps were transferred into a 6-well ultra-low adherence 568 plate (Corning) containing EB formation medium (hES medium supplemented with 50ng/ml 569 BMP4 (Invitrogen), 50ng/ml VEGF (Peprotech) and 20 ng/ml SCF (Miltenyi)) to form EBs. A 570 50% medium change was performed every second day. On day 5 EBs were harvested. 571
Approximately 60-80 EBs were transferred into a T75 flask containing factory medium (X-572 VIVO 15 (Lonza) supplemented with 2 mM L-Glutamine, 50 µM 2-Mercaptoethanol, 100 573 ng/ml M-CSF and 25 ng/mL IL-3, 100 U/ml penicillin and 100 µg/ml streptomycin (all Gibco)). 574
The EBs were fed weekly with fresh factory medium. After approximately two weeks EBs 575 started to produce non-adherent macrophage precursors, which were harvested from the 576 supernatant of EB cultures through a 70 µM cell strainer. Cells were differentiated into 577 mature adherent macrophages for 7 days in macrophage medium (X-VIVO 15 supplemented 578 with 2 mM L-Glutamine, 100 ng/ml M-CSF, 100 U/ml penicillin and 100 µg/ml streptomycin). 579 580 ELISA 581 19 iPSC-derived macrophages were harvested from EB cultures, counted and seeded at 582 25,000 cells per well into 96-well tissue culture plates in triplicates per condition. 583
Macrophages were cultured in macrophage differentiation medium for 7 days, and then 584 activated with 50 ng/ml LPS (Sigma-Aldrich) in fresh macrophage differentiation medium for 585 4 h. For inhibitor treatments cells were incubated with 50 ng/ml LPS and 3 µM GW or GI for 4 586 h. Cell culture supernatants were collected and cleared from cells by centrifugation. TNFα in 587 supernatants was measured by ELISA (Human TNF alpha ELISA Ready-SET-Go, 588 eBioscience (88-7346-86)) according to the manufacturer's instructions. Macrophages were 589 lysed in Trition X-100 lysis buffer and protein concentration was determined using a BCA 590 assay (Thermo Scientific). The amount of TNFα in the supernatant was normalised to the 591 protein concentration of the corresponding cell lysate to adjust for differences in TNFα 592 release due to cell numbers. 593
594
Mouse work 595
Commercially available Frmd8 -/mouse ES cells from KOMP Repository at UC Davis 596 were used to generate Frmd8 -/mice. The mouse ES cells (C57BL/6NTac strain) were 597 injected into blastocysts of Balb/c mice. Chimeras were bred to C57BL/6 to generate 598
Frmd8 +/mice that were used for breeding of the colony and the generation of Frmd8 -/mice. 599
The mouse work was performed under project licenses 80/2584 and 30/2306. Mouse tissues 600 were collected from sacrificed animals and stored on dry ice or at -80°C. Tissues were lysed 601 in Triton X-100 RIPA buffer (1% Triton X-100, 150 mM NaCl, 50 mM Tris-HCl (pH 7.5), 0.1% 602 SDS, 0.5% sodium deoxycholate) supplemented with EDTA-free protease inhibitor mix and 603 10 mM 1,10-Phenanthroline using a tissue homogeniser (Omni International). Lysates were 604 cleared from cell debris by centrifugation (20,000 g, 4°C, 10 min). Protein concentrations of 605 tissue lysates were determined using a BCA assay. 606 607
Statistical analysis and data presentation 608
Values are expressed as means of at least three independent experiments with error 609 bars representing the standard deviation. Unpaired, two-tailed t-tests were used for statistical 610 analysis. Shedding assays and ELISA data was analysed using a Mann-Whitney test. Flow 611 cytometry blots shown represent one from at least three experiments with similar outcome. 612 20 Acknowledgements 613
We gratefully acknowledge the support of Oxford's Advanced Proteomics Facility for 614 our mass spectrometry based proteomic screen and Monika Stegmann for statistical analysis 615 of the results. We also thank Genome Engineering Oxford, specifically Joey Riepsaame and 616 Andrew Bassett, who helped us to design and clone guide RNAs for CRISPR/Cas9 gene 617 editing. We are thankful for the assistance in animal work from the staff of the mouse facility 618 and for support from Elizabeth Robertson, Jonathan Godwin, Angela Moncada Pazos, and 619 Clémence Levet. Immunofluorescent microscopy was performed in Oxford's Micron imaging 620 facility. We thank members of the Freeman lab for their extensive support throughout this 621 project and their advice on the manuscript. We thank Stefan Düsterhöft and Boris Sieber for 622 providing reagents. 
